Details for Patent: 9,206,217

Title:	Nucleoside phosphoramidates
Abstract:	Disclosed herein are nucleoside phosphoramidates and their use as agents for treating viral diseases. These compounds are inhibitors of RNA-dependent 5 RNA viral replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication and for treatment of hepatitis C infection in mammals.
Inventor(s):	Ross; Bruce (El Granada, CA), Sofia; Michael Joseph (Doylestown, PA), Pamulapati; Ganapati Reddy (San Ramon, CA), Rachakonda; Suguna (Twinsburg, OH), Zhang; Hai-Ren (San Jose, CA), Chun; Byoung-Kwon (Robbinsville, NJ), Wang; Peiyuan (Totowa, NJ)
Assignee:	Gilead Pharmasset LLC (Foster City, CA)
Filing Date:	Jan 02, 2013
Application Number:	13/732,725
Claims:	1. cited by applicant . Claims of U.S. Appl. No. 12/783,680 as filed May 20, 2010. cited by applicant . Claims of U.S. Appl. No. 13/099,671 as filed Sep. 4, 2012. cited by applicant . Claims of U.S. Appl. No. 13/956,195 as amendment Oct. 21, 2013. cited by applicant . Claims of U.S. Appl. No. 14/013,237 as amended Aug. 30, 2013. cited by applicant . Claims of U.S. Appl. No. 14/057,675 as amended Oct. 22, 2013. cited by applicant . Communication enclosing Partial European Search Report for European Patent Application No. 13159791.6 dated Feb. 6, 2014 (6 pages). cited by applicant . Communication pursuant to Rule 114(2) for European Application No. 11714465.9 dated Dec. 1, 2014 (3 pages). cited by applicant . Engish Translation of Office Action for Taiwanese Application No. 100111246 dated Sep. 15, 2014 (3 pages). cited by applicant . English Translation for Office Action in Korean Application No. 10-2014-7032628 dated Feb. 6, 2015 (8 pages). cited by applicant . English Translation of Office Action for Chilean Application No. 716-2011 dated Oct. 9, 2014 (8 pages). cited by applicant . English Translation of Office Action for Eurasian Application No. 201290993 dated Sep. 17, 2014 (3 pages). cited by applicant . English Translation of Office Action for Mexican Application No. MX/a/2012/011171 dated Aug. 7, 2014 (3 pages). cited by applicant . English Translation of Office Action for Panamanian Application No. 89230-02 dated Jun. 17, 2014 (4 pages). cited by applicant . English Translation of Office Action in Chilean Application No. 903-13 dated Dec. 3, 2014 (8 pages). cited by applicant . English translation of Office Action in Japan Application No. 2012-512043 dated Mar. 17, 2015 (8 pages). cited by applicant . English translation of Office Action in Japanese Application No. 2013-502843 dated Feb. 19, 2015 (3 pages). cited by applicant . English Translation of Office Action in Korean Application No. 10-2011-7030501 dated Mar. 25, 2015 (4 pages). cited by applicant . Examination Report for New Zealand Application No. 603232 dated Dec. 4, 2014 (3 pages). cited by applicant . Examination Report in Australia Application No. 2011235112 dated Feb. 5, 2015 (3 pages). cited by applicant . Grakoui et al., "Characterization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase- Dependent Polyprotein Clevage Sites," J. Virol., (1993), 67(5):2832-2843. cited by applicant . Griffith et al., "HCV Anti-viral Agents," Annual Reports in Medicinal Chemistry, (2004), 39:223-237. cited by applicant . International Search Report and Written Opinion mailed Jun. 15, 2006 for International Application No. PCT/US05/25916. cited by applicant . International Search Report and Written Opinion mailed Nov. 7, 2011 for International Patent Application No. PCT/US2011/030725. cited by applicant . Written Opinion in Internation Application No. PCT/EP2006/069060 mailed Jan. 30, 2007. cited by applicant . Written Opinion in Internation Application No. PCT/US2005/032406 mailed May 8, 2008. cited by applicant . Written Opinion in Internation Application No. PCT/US2010/035641 mailed Sep. 28, 2010. cited by applicant . Koonin, et al., "Evolution and Taxonomy of Positive-Strand RNA Viruses: Implications of Comparatives Analysis of Amino Acid Sequences," Crir. Rev. Biochem. Malec. Biol. 1993, 28, 375-430. cited by applicant . Lalezari, J., et al., "Once Daily PSI-7977 Plus PegIFN/RBV in a Phase 28 Trial: Rapid Virologic Suppression in Treatment-Naive Patients with HGV GT2/GT3," J. Hepatology (2011) 54:S28 (Abstract #61 ). cited by applicant . Lam, Angela M., et al., "PSI-7851, a Pronucleotide of beta-D-2'-Deoxy-2'-Fluoro-2'-C-Methyluridine Monophosphate, Is a Potent and Pan-Genotype Inhibitor of Hepatitis C Virus Replication," Antimicrob. Agents & Chemother. (2010) 54 (8):3187-3196. cited by applicant . Lawitz, E., et al., "Once Daily Dual-Nucleotide Combination of PSI-938 and PSI-7977 Provides 94% HGV RNA <Lod at Day 14: First Purine/Pyrimidine Clinical Combination Data (the Nuclear Study)," J. Hepatology (2011) 54:S543 (Abstract #1370). cited by applicant . McGuigan et al., Bioorg & Med. Chem. (1999), 42(3):393-399. cited by applicant . McGuigan et al., Bioorg. & Med. Chem. Lett., (2010), 20:4850-4854. cited by applicant . Murakami, Eisuke, et al., "Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977," J. Biol. Chem., (2010), 285(45):34337-34347. cited by applicant . Office Action for Pakistani Application No. 233/2011 dated Mar. 28, 2014 (2 pages). cited by applicant . Office Action for Pakistani Application No. 748/2012 dated Sep. 4, 2014 (2 pages). cited by applicant . Office Action in Canada Application No. 2819700 dated Mar. 6, 2015 (4 pages). cited by applicant . Office Action in Canadian Application No. 2794669 dated Jan. 15, 2015 (4 pages). cited by applicant . Office Action in Chilean Application No. 716-2011 dated Mar. 30, 2015( 6 pages). cited by applicant . Office Action in Chinese Application No. 201080032541.2 dated Dec. 3, 2014 (3 pages). cited by applicant . Office Action in Chinese Application No. 201180017181.3 dated Aug. 19, 2014 (7 pages). cited by applicant . Office action in Chinese Application No. 20118017181.3 dated Decemeber 8, 2014 (9 pages). cited by applicant . Office Action in Israel Application No. 237471 dated Mar. 10, 2015 (3 pages). cited by applicant . Office Action in Mexican Application No. MX/a/2012/011171 dated Mar. 30, 2015 (6 pages). cited by applicant . Office action in U.S. Appl. No. 11/353,597 dated Dec. 2, 2008. cited by applicant . Office action in U.S. Appl. No. 13/925,078 dated Apr. 23, 2015 (7 pages). cited by applicant . Office Action in Ukraine Application No. A 2012 12444 dated Jan. 27, 2015 (4 pages). cited by applicant . Roman et al., J. Med. Chem. (2010), 53(21):7675-7681. cited by applicant . Search and Examination Report in African Regional Intellectual Property Organization Application No. AP/P/2012/006543 dated Jan. 9, 2015 (4 pages). cited by applicant . Search Report and Written Opinion for Singapore Application No. 2011086105 dated Apr. 30, 2014 (20 pages). cited by applicant . Sofia, "Discovery of a beta-D-2'-Deoxy-2'-alpha-fluoro-2'-beta-C-methyluridine Nucleotide Prodrug (PSI-7977) for the Treament of Hepatitis C Virus," J. Med. Chem., (2010), 53. cited by applicant . Stuyver et al., "Inhibition of the Subgenomic Hepatitis C Virus Replicon in Huh-7 Cells by 2'-Deoxy-2'- Fluorocytidine," Antimicrobial Agents and Chemotherapy, (2004), 48(2):651-654. cited by applicant . Subsequent Substantive Examination Report for Philippines Application No. 1/2011/502433 dated Jan. 13, 2015 (1 page). cited by applicant . Supplemntary Serarch Report in Singapore Application No. 201207206-2 dated Mar. 17, 2015, (7 pages). cited by applicant . Zhou, Xiao-Jian, et al., "Safety and Pharmacokinetics of IDX184, a Liver-Targeted Nucleotide Polymerase Inhibitor of Hepatitis C Virus, in Healthy Subjects," Antimicrob. Agents & Chemother, (2011), 55(1 ):76-81. cited by applicant . Zhu et al., "Design and synthesis of HCV agents with sequential triple inhibitory potentials," Bioorg. & Med. Chem. Lett., (2010), 20(17):5212-5216. cited by applicant.

Primary Examiner: Olson; Eric
Assistant Examiner: Miller; Dale R
Attorney, Agent or Firm: Sheppard Mullin Richter & Hampton LLP